NKTR Quote, Financials, Valuation and Earnings

Ironwood Pharmaceuticals, Inc. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of 32.84%. Nektar Therapeutics's return on equity of -327.67% beat Ironwood Pharmaceuticals, Inc.'s return on equity of --.

Nektar Therapeutics has a consensus price target of $118.71, signalling upside risk potential of 111.99%. On the other hand Ironwood Pharmaceuticals, Inc. has an analysts' consensus of $3.17 which suggests that it could fall by -31.01%. Given that Nektar Therapeutics has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe Nektar Therapeutics is more attractive than Ironwood Pharmaceuticals, Inc..

Nektar Therapeutics has a beta of 1.341, which suggesting that the stock is 34.126% more volatile than S&P 500. In comparison Ironwood Pharmaceuticals, Inc. has a beta of 0.172, suggesting its less volatile than the S&P 500 by 82.759%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ironwood Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Ironwood Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $11.8M, which are smaller than Ironwood Pharmaceuticals, Inc. quarterly revenues of $122.1M. Nektar Therapeutics's net income of -$35.5M is lower than Ironwood Pharmaceuticals, Inc.'s net income of $40.1M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Ironwood Pharmaceuticals, Inc.'s PE ratio is 29.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 57.74x versus 2.29x for Ironwood Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lyell Immunopharma, Inc. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of -258973.33%. Nektar Therapeutics's return on equity of -327.67% beat Lyell Immunopharma, Inc.'s return on equity of -86.7%.

Nektar Therapeutics has a consensus price target of $118.71, signalling upside risk potential of 111.99%. On the other hand Lyell Immunopharma, Inc. has an analysts' consensus of $29.67 which suggests that it could grow by 25.12%. Given that Nektar Therapeutics has higher upside potential than Lyell Immunopharma, Inc., analysts believe Nektar Therapeutics is more attractive than Lyell Immunopharma, Inc..

Nektar Therapeutics has a beta of 1.341, which suggesting that the stock is 34.126% more volatile than S&P 500. In comparison Lyell Immunopharma, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lyell Immunopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Lyell Immunopharma, Inc. pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $11.8M, which are larger than Lyell Immunopharma, Inc. quarterly revenues of $15K. Nektar Therapeutics's net income of -$35.5M is higher than Lyell Immunopharma, Inc.'s net income of -$38.8M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Lyell Immunopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 57.74x versus 85,977.32x for Lyell Immunopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Owlet, Inc. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of 12.58%. Nektar Therapeutics's return on equity of -327.67% beat Owlet, Inc.'s return on equity of --.

Nektar Therapeutics has a consensus price target of $118.71, signalling upside risk potential of 111.99%. On the other hand Owlet, Inc. has an analysts' consensus of $17.00 which suggests that it could grow by 45.42%. Given that Nektar Therapeutics has higher upside potential than Owlet, Inc., analysts believe Nektar Therapeutics is more attractive than Owlet, Inc..

Nektar Therapeutics has a beta of 1.341, which suggesting that the stock is 34.126% more volatile than S&P 500. In comparison Owlet, Inc. has a beta of 1.713, suggesting its more volatile than the S&P 500 by 71.275%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Owlet, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Owlet, Inc. pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $11.8M, which are smaller than Owlet, Inc. quarterly revenues of $32M. Nektar Therapeutics's net income of -$35.5M is lower than Owlet, Inc.'s net income of $4M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Owlet, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 57.74x versus 1.96x for Owlet, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals, Inc. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of 40.17%. Nektar Therapeutics's return on equity of -327.67% beat Rigel Pharmaceuticals, Inc.'s return on equity of 273.99%.

Nektar Therapeutics has a consensus price target of $118.71, signalling upside risk potential of 111.99%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $51.60 which suggests that it could grow by 49.05%. Given that Nektar Therapeutics has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Nektar Therapeutics is more attractive than Rigel Pharmaceuticals, Inc..

Nektar Therapeutics has a beta of 1.341, which suggesting that the stock is 34.126% more volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.111, suggesting its more volatile than the S&P 500 by 11.137%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $11.8M, which are smaller than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.5M. Nektar Therapeutics's net income of -$35.5M is lower than Rigel Pharmaceuticals, Inc.'s net income of $27.9M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Rigel Pharmaceuticals, Inc.'s PE ratio is 5.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 57.74x versus 2.25x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.